Advanced search
Log in
Forgot password ?
Remember
Or log in with
Google
Twitter
Facebook
Apple
Sign up
Email Registration
Or log in with
Google
Twitter
Facebook
Apple
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Français (Suisse)
Italiano
Nederlands (Nederland)
Nederlands (België)
Markets
Equities
Top Capitalization
United States
North America
Europe
Asia
Middle East
Sector Research
Financial Calendar
Equities Analysis
Most popular
ALPHABET INC.
MICROSOFT CORPORATION
META PLATFORMS, INC.
APPLE INC.
AMAZON.COM, INC.
TESLA, INC.
NVIDIA CORPORATION
Indexes
Homepage
Rankings
Europe
America
Asia
Africa
Index Analysis
Indexes News
S&P 500
DOW JONES
NASDAQ 100
TSX COMP
FTSE 100
DAX
CAC 40
EURO STOXX 50
Currency / Forex
Homepage
Rankings
Currency Cross Rate
Currency Converter
Forex Analysis
Currencies News
USD / EUR
USD / CAD
USD / MXN
USD / BRL
USD / INR
Commodities
Homepage
Energy
Precious metals
Agriculture
Industrial Metals
Livestock and Cattle
GOLD
CRUDE OIL (WTI)
CRUDE OIL (BRENT)
SILVER
PLATINUM
Cryptocurrencies
Homepage
Rankings
Charts
Analysis
News
BITCOIN
ETHEREUM
BINANCE COIN
SOLANA
CARDANO
FTX TOKEN
Interest Rates
Homepage
Developed Nations
Emerging Countries
ETFs Rates
ETF
Rankings and News
Advanced Search
News
All News
World
United States
Europe
North America
South America
Asia
Africa
Middle East
Emerging
Companies
All News
Analyst Reco.
Rumors
IPOs
Capital Markets Transactions
New Contracts
Profit Warnings
Appointments
Press Releases
Security Transactions
Earnings reports
New markets
New products
Corporate strategies
Legal risks
Share buybacks
Mergers and acquisitions
Call Transcripts
Guidance
Indexes
Currency / Forex
Commodities
Cryptocurrencies
ETF
Interest Rates
Economy
Themes
Asset Management
Activism
Climate and ESG
Cybersecurity
Geopolitics
Central Banks
Private Equity
Inflation
Business Leaders
Sectors
All our articles
Most Read News
Hot News
Analysis
All Analysis
Must Read
Equities
Indexes
Currencies
Commodities
Cryptocurrencies
Stock Trading Strategies
All
America
Europe
Asia
Our Shows
Shows
World Press Review
Pump & Dump
Must Watch
Satirical Cartoon
Today's Editorial
Crypto Recap
Stock Picks
Portfolios
Virtual Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Watchlists
My Watchlists
Watchlists
My previous session
My most visited
Most popular
Investment Style
Homepage
Trend-Following Stocks
Momentum stocks
Undervalued stocks
Quality stocks
Yield stocks
ESG stocks
Investment Themes
Homepage
Sin stocks
Education
Robotics
The Golden Age of Video Games
In Vino Veritas
Boats
Rankings
Top Movers
Top Movers
Unusual volumes
New Historical Highs
New Historical Lows
Long Term
Top Fundamentals
Top Fundamentals
Sales growth
Earnings Growth
Profitability
Finances
Rankings Valuation
Rankings Valuation
P/E ratio
Enterprise value
Yield
Top Consensus
Top Consensus
Analyst Opinion
Target price
Estimates Revisions
Divergence
Top Technicals
Top RSI
Unusual volumes
GAPS
STIM
Breakouts
Trends
Volatility
Top ranking ESG
Top ranking ESG
Environnement
Social
Gouvernance
Rankings Coverage
Screeners
Stock Screener Home
Investment Themes
The Cannabis Industry
Robotics
Financial Data
The Golden Age of Video Games
In Vino Veritas
Cybersecurity
Technical Rankings
Oversold stocks
Overbought stocks
Close to resistance
Close to support
Accumulation Phases
Most volatile stocks
Fundamental Rankings
Top Investor Rating
Top Trading Rating
Top Consensus
Low valuations
My Screeners
All my stocks
Watchlists
Virtual Portfolios
Tools
MarketScreener tools
Stock Screener
iPhone App
Expert tools
Stock Screener PRO
Portfolio Creator
Event Screener
Dynamic Chart
Financial Calendar
Economic Calendar
Currency Converter
ProRealTime Trading
Our Services
Our subscriptions
Our Stock Picks
Stock Screener
Thematic Investment Lists
MarketScreener Portfolios
European Portfolio
USA Portfolio
Asian Portfolio
Homepage
Equities
Sweden
Nasdaq Stockholm
Calliditas Therapeutics AB (publ)
News
Summary
CALTX
SE0010441584
CALLIDITAS THERAPEUTICS AB (PUBL)
(CALTX)
Add to my list
Report
Delayed Nasdaq Stockholm -
11:29:56 2023-02-03 am EST
97.10
SEK
-0.82%
02/02
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA nephropathy
AQ
02/02
Calliditas Therapeutics AB Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in IgA Nephropathy
CI
01/31
Calliditas Therapeutics : Press Release dated January 31, 2023 - Form 6-K
PU
Summary
Quotes
Charts
News
Ratings
Calendar
Company
Financials
Consensus
Revisions
Funds
Summary
Most relevant
All News
Analyst Reco.
Other languages
Press Releases
Official Publications
Sector news
European ADRs Move Higher in Friday Trading
10/21/2022 | 11:19am EST
Send by mail :
Name :
First name :
From
*
:
To
*
:
(You can enter multiple email addresses separated by commas)
Message :
*
Required fields
© MT Newswires 2022
Stocks mentioned in the article
Change
Last
1st jan.
ACHILLES CORPORATION
-0.08%
1244
0.16%
ACHILLES THERAPEUTICS PLC
-0.83%
1.2
33.33%
ADAPTIMMUNE THERAPEUTICS PLC
-4.05%
1.66
18.49%
ARCELORMITTAL
0.53%
28.61
16.42%
BICYCLE THERAPEUTICS PLC
-3.55%
27.44
-7.30%
BIONTECH SE
-1.62%
142.06
-5.43%
CALLIDITAS THERAPEUTICS AB (PUBL)
-0.82%
97.1
5.03%
CELLECTIS S.A.
-20.67%
2.38
19.78%
ENDAVA PLC
-0.94%
93.12
21.73%
INTERCONTINENTAL HOTELS GROUP PLC
0.10%
5784
21.92%
MORPHOSYS AG
-1.68%
19
43.83%
MYNARIC AG
3.82%
16.3
0.62%
ORCHARD THERAPEUTICS PLC
1.53%
0.5774
53.29%
RIO TINTO PLC
1.06%
6128
5.69%
SILENCE THERAPEUTICS PLC
30.00%
3.25
0.00%
SPARK NETWORKS SE
5.61%
1.13
73.85%
WISEKEY INTERNATIONAL HOLDING AG
-0.90%
0.2205
31.88%
All news about CALLIDITAS THERAPEUTICS AB (PUBL)
02/02
Calliditas Receives Conditional Marketing Authorization from UK MHRA for Kinpeygo in Ig..
AQ
02/02
Calliditas Therapeutics AB Receives Conditional Marketing Authorization from UK MHRA fo..
CI
01/31
Calliditas Therapeutics : Press Release dated January 31, 2023 - Form 6-K
PU
01/31
Number of shares and votes in Calliditas Therapeutics
AQ
2022
Calliditas Therapeutics Says China's Center for Drug Evaluation Recommends Kidney Disea..
MT
2022
Calliditas Therapeutics JV's Primary IgA Nephropathy Drug Gets Priority Review Recommen..
MT
2022
China CDE/NMPA Recommends Priority Review for Nefecon for the Treatment of Primary IgA ..
AQ
2022
Calliditas Therapeutics Announces China CDE/NMPA Recommends Priority Review for Nefecon..
CI
2022
Number of shares and votes in Calliditas Therapeutics
AQ
2022
Calliditas Therapeutics Chief Executive Buys 50,000 Shares in Warrant Program
MT
More news
Analyst Recommendations on CALLIDITAS THERAPEUTICS AB (PUBL)
2021
HC Wainwright Adjusts Calliditas Therapeutics' Price Target to $62 From $52, Reiterates..
MT
2021
Citigroup Adjusts Calliditas Therapeutics' Price Target to $84 From $51, Reiterates Buy..
MT
2021
Analyst recommendations: Alibaba, Goldman Sachs, Monday.com, Sha..
More recommendations
Financials
SEK
USD
Sales 2022
634 M
60,3 M
60,3 M
Net income 2022
-469 M
-44,7 M
-44,7 M
Net cash 2022
148 M
14,1 M
14,1 M
P/E ratio 2022
-12,3x
Yield 2022
-
Capitalization
5 785 M
551 M
551 M
EV / Sales 2022
8,89x
EV / Sales 2023
2,35x
Nbr of Employees
98
Free-Float
86,1%
More Financials
Chart CALLIDITAS THERAPEUTICS AB (PUBL)
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Full-screen chart
Technical analysis trends CALLIDITAS THERAPEUTICS AB (PUBL)
Short Term
Mid-Term
Long Term
Trends
Neutral
Neutral
Neutral
Technical analysis
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
More Financials
Consensus
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
97,10 SEK
Average target price
246,80 SEK
Spread / Average Target
154%
Consensus
EPS Revisions
Please enable JavaScript in your browser's settings to use dynamic charts.
More Estimates Revisions
Managers and Directors
Renée Julie Elisabet Aguiar-Lucander
Chief Executive Officer
Fredrik Johansson
Chief Financial Officer
Elmar J. Schnee
Chairman
Patrik Sobocki
Chairman
Johan Erik Häggblad
Chief Scientific Officer
More about the company
Sector and Competitors
1st jan.
Capi. (M$)
CALLIDITAS THERAPEUTICS AB (PUBL)
5.03%
551
MERCK KGAA
2.76%
87 710
KYOWA KIRIN CO. LTD.
-4.57%
11 831
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD
3.16%
5 822
SK BIOPHARMACEUTICALS CO., LTD.
-0.69%
4 554
BETTA PHARMACEUTICALS CO., LTD.
22.24%
3 943
More Results
Slave